false
0001429260
0001429260
2024-05-23
2024-05-23
0001429260
us-gaap:CommonStockMember
2024-05-23
2024-05-23
0001429260
FBIO:SeriesACumulativeRedeemablePerpetualPreferredStockMember
2024-05-23
2024-05-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
May 23, 2024
Fortress Biotech, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
001-35366 |
|
20-5157386 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1111 Kane Concourse, Suite 301
Bay Harbor Islands, FL 33154 |
(Address of Principal Executive Offices) |
(781) 652-4500
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act. |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act. |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2b under
the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act. |
Securities registered pursuant to Section 12 (b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common Stock |
FBIO |
Nasdaq Capital Market |
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock |
FBIOP |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As described under Item 5.07 of this Current Report
on Form 8-K (the “Current Report”), on May 23, 2024, the stockholders of Fortress Biotech, Inc. (the “Company”
or “Fortress”) voted at the Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”)
to: (i) approve an amendment (the “Incentive Plan Amendment”) to the Company’s 2013 Stock Incentive Plan (the
“Incentive Plan”) to increase the shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), issuable thereunder by 10,000,000 shares and increase the annual share limit for participants pursuant to grants of
stock options and stock appreciation rights, (ii) approve an amendment (the “ESPP Amendment”) to the Company’s
2012 Employee Stock Purchase Plan (the “ESPP”) to increase the number of shares of the Company’s common stock
issuable thereunder by 1,000,000 shares and increase the number of shares eligible for purchase during an “Offering,” and
(iii) approve an amendment (the “LTIP Amendment” and together with the Incentive Plan Amendment and the ESPP Amendment,
the “Plan Amendments”) to the Company’s Amended and Restated Long Term Incentive Plan (“LTIP”)
to extend the term of the plan to July 15, 2035 and to make certain related changes.
The Company’s Board of Directors previously
approved the Plan Amendments subject to stockholder approval at the 2024 Annual Meeting. The Plan Amendments became effective at the time
of stockholder approval.
Copies of the Incentive Plan Amendment, the ESPP
Amendment and the LTIP Amendment are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to this Current Report and are incorporated
by reference in this Item 5.02. The material terms of the Incentive Plan, the ESPP and the LTIP, each as so amended, are described in
the Company’s definitive proxy statement on Schedule 14A for the 2024 Annual Meeting (the “2024 Proxy Statement”)
filed with the Securities and Exchange Commission on April 5, 2024.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 23, 2024, the Company held the 2024 Annual
Meeting at 10:00 a.m. Eastern Time by means of an online virtual meeting platform.
At the 2024 Annual Meeting, the following five
proposals were approved: (i) the election of eight directors to hold office until the 2025 annual meeting of stockholders or until such
director resigns or is removed from office; (ii) the ratification of the appointment of KPMG LLP as Fortress’s independent registered
public accounting firm for the year ending December 31, 2024; (iii) an amendment to the Incentive Plan to increase the number of shares
of the Company’s common stock issuable thereunder by 10,000,000 shares and increase the annual share limit for participants pursuant
to grants of stock options and stock appreciation rights; (iv) an amendment to the ESPP to increase the number of shares of the Company’s
common stock issuable thereunder by 1,000,000 shares and increase the number of shares eligible for purchase during an “Offering”;
and (v) an amendment to the LTIP to extend the term of the plan to July 15, 2035 and to make certain related changes. The five proposals
are described in detail in the 2024 Proxy Statement.
Proposal 1
The votes with respect to the election of eight
directors to hold office until the 2025 annual meeting of stockholders were as follows:
Director | |
Total Votes For | | |
Total Votes Against | | |
Abstentions | | |
Broker Non-
Votes | |
Lindsay A. Rosenwald, M.D. | |
| 7,879,152 | | |
| 279,498 | | |
| 55,513 | | |
| 6,103,441 | |
Jimmie Harvey, Jr., M.D. | |
| 7,818,574 | | |
| 313,504 | | |
| 82,085 | | |
| 6,103,441 | |
Malcolm Hoenlein | |
| 7,859,535 | | |
| 272,540 | | |
| 82,088 | | |
| 6,103,441 | |
Dov Klein, CPA | |
| 7,826,677 | | |
| 305,682 | | |
| 81,804 | | |
| 6,103,441 | |
J. Jay Lobell | |
| 7,594,293 | | |
| 537,567 | | |
| 82,303 | | |
| 6,103,441 | |
Kevin L. Lorenz, J.D. | |
| 7,887,576 | | |
| 243,771 | | |
| 82,816 | | |
| 6,103,441 | |
Lucy Lu, M.D. | |
| 7,705,775 | | |
| 446,504 | | |
| 61,884 | | |
| 6,103,441 | |
Michael S. Weiss | |
| 7,784,677 | | |
| 350,576 | | |
| 78,910 | | |
| 6,103,441 | |
Proposal 2
The vote with respect to the ratification of KPMG
LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2024 was as follows:
Total Votes For | |
Total Votes Against | |
Abstentions |
13,930,260 | |
324,833 | |
62,511 |
Proposal 3
The vote with respect to the approval of an amendment
to Fortress’s Incentive Plan was as follows:
Total Votes For | |
Total Votes Against | |
Abstentions | |
Broker Non-Votes |
6,983,739 | |
1,162,676 | |
67,748 | |
6,103,441 |
Proposal 4
The vote with respect to the approval of an amendment
to Fortress’s ESPP was as follows:
Total Votes For | |
Total Votes Against | |
Abstentions | |
Broker Non-Votes |
7,477,954 | |
687,613 | |
48,596 | |
6,103,441 |
Proposal 5
The vote with respect to the approval of an amendment
to Fortress’s LTIP was as follows:
Total Votes For | |
Total Votes Against | |
Abstentions | |
Broker Non-Votes |
7,096,492 | |
905,389 | |
212,282 | |
6,103,441 |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Fortress Biotech, Inc. |
|
(Registrant) |
|
|
Date: May 29, 2024 |
|
|
|
|
By: |
/s/ Lindsay
A. Rosenwald, M.D. |
|
|
Lindsay A. Rosenwald, M.D. |
|
|
Chairman, President and Chief Executive Officer |
Exhibit 10.1
AMENDMENT
TO THE COMPANY’S 2013 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES
OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER
1. Section 3(a) of the 2013 Plan is hereby replaced in its
entirety so that such section reads as follows:
3. STOCK SUBJECT TO THE PLAN
(a) Subject to the provisions of Section 12
below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive Stock Options) is Eleven
Million Five Hundred Thirty-Three Thousand Three Hundred Thirty-Three (11,533,333) Shares. The Shares may be authorized, but unissued,
or reacquired Common Stock.
2. Section 6(g) of the 2013 Plan is
hereby replaced in its entirety so that such section reads as follows:
6. TERMS AND CONDITIONS OF AWARDS
(g) Individual Option and SAR Limit.
The maximum number of Shares with respect to which Options and SARs may be granted to any Grantee in any calendar year shall be One Million
(1,000,000) Shares. The foregoing limitation shall be adjusted proportionately in connection with any change in the Company’s capitalization
pursuant to Section 12 below. To the extent required by Section 162(m) of the Code or the regulations thereunder, in applying
the foregoing limitations with respect to a Grantee, if any Option or SAR is canceled, the canceled Option or SAR shall continue to count
against the maximum number of Shares with respect to which Options and SARs may be granted to the Grantee. For this purpose, the repricing
of an Option (or in the case of an SAR, the base amount on which the stock appreciation is calculated is reduced to reflect a reduction
in the Fair Market Value of the Common Stock) shall be treated as the cancellation of the existing Option or SAR and the grant of a new
Option or SAR.
Exhibit 10.2
AMENDMENT TO THE
FORTRESS BIOTECH, INC.
2012 EMPLOYEE STOCK PURCHASE PLAN
This amendment (the “Amendment”) to
the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan, as amended (the “Plan”), is hereby adopted this 23rd day
of May, 2024, by the Board of Directors (the “Board”) of Fortress Biotech, Inc. (the “Company”).
WITNESSETH:
WHEREAS, the Company
adopted the Plan for the purposes set forth therein;
WHEREAS, pursuant to Section 21 of
the Plan, the Board has the right to amend the Plan with respect to certain matters, provided that any material increase in the number
of Shares available under the Plan shall be subject to stockholder approval; and
WHEREAS, the Board has approved and authorized
this Amendment to the Plan and has recommended that the stockholders of the Company approve this Amendment;
NOW, THEREFORE, BE IT RESOLVED, that the
Plan is hereby amended, subject to and effective as of the date of stockholder approval hereof, in the following particulars:
1. Section 3 of the Plan is hereby replaced
in its entirety so that such section reads as follows:
“3. Share Reserve. The maximum number of
shares which may be issued under the Plan shall be one million one hundred thirty-three thousand three hundred thirty-three (1,333,333)
shares of the Company’s authorized but unissued common stock, $.001 par value (the “Shares”). In the event that any
Purchase Right for any reason expires or is canceled or terminated, the Shares allocable to the unexercised portion of such Purchase Right
may again be subjected to a Purchase Right.”
2. Section 7(b) of the Plan is hereby
replaced in its entirety so that such section reads as follows:
“(b) 5,000 Shares.”
3. Except as specifically set forth herein, the
terms of the Plan shall be and remain unchanged, and the Plan as amended shall remain in full force and effect.
The foregoing is hereby acknowledged as being the Amendment to the
Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan, as amended, as adopted by the Board on March 28, 2024, and approved
by the Company’s stockholders on May 23, 2024.
Exhibit 10.3
AMENDMENT TO THE
FORTRESS BIOTECH, INC.
AMENDED AND RESTATED LONG TERM INCENTIVE PLAN
This amendment (the “Amendment”)
to the Fortress Biotech, Inc. Amended and Restated Long Term Incentive Plan (the “LTIP”), is hereby adopted this 23rd
day of May, 2024, by the Board of Directors (the “Board”) of Fortress Biotech, Inc. (the “Company”).
WITNESSETH:
WHEREAS, the Company
adopted the LTIP for the purposes set forth therein;
WHEREAS, pursuant
to Section 7 of the LTIP, the Board has the right to amend the plan with respect to certain matters, subject to stockholder approval;
and
WHEREAS, the Board
and the Compensation Committee of the Board have each approved and authorized this Amendment to the LTIP and have recommended that the
stockholders of the Company approve this Amendment;
NOW, THEREFORE, BE IT
RESOLVED, that the LTIP is hereby amended, subject to and effective as of the date of stockholder approval hereof, in the following
particulars:
1. Section 4(b) of
the LTIP is hereby replaced in its entirety so that such section reads as follows:
“(b) On January 1 of each calendar
year following the Effective Date, the Company will grant to each Participant a number of restricted shares of common stock of the Company
equal to one percent (1%) of the total outstanding shares of common stock of the Company determined on a fully-diluted, as-converted into
common stock basis as of such date, multiplied by the percentage of achievement of the goals and objectives established for the Participant
by the Committee (the “Restricted Shares”), provided that the Participant must be employed by, or otherwise providing
services to, the Company on such date in order to receive the grant of Restricted Shares, and provided further that when there are eligible
Participating Entities, the 1% equity award will be allocated as determined by the Committee between the Participating Entity and the
applicable individual Participant, such that, between a Participant and his respective Participating Entity, if any, the total amount
awarded under this Section 4(b) shall not exceed one percent (1%) of the total outstanding shares of common stock of the Company.
Such goals and objectives shall be set by the Committee at the beginning of each year ending on December 31, and the determination
of the achievement percentage of the goals and objectives shall be determined by the Committee as of the end of such period. Such Restricted
Shares that are issued prior to July 16, 2025 shall be subject to the Company’s Repurchase Option (as defined below) until
both of the following conditions are met: (i) there is an increase in the market capitalization of the Company of at least $100,000,000
(measured from the Effective Date) at any time following the grant, and (ii) the Participant is either in the service of the Company
as an employee, a Board member, or a consultant on the 10th anniversary of Effective Date, or the
Participant has had an involuntary Separation from Service (as defined below) from the Company. Such Restricted Shares that are issued
on or after July 16, 2025 shall be subject to the Company’s Repurchase Option (as defined below) until both of the following
conditions are met: (i) there is an increase in the market capitalization of the Company of at least $100,000,000 (measured from
July 16, 2025) at any time following the grant, and (ii) the Participant is either in the service of the Company as an employee,
a Board member, or a consultant on July 15, 2035, or the Participant has had an involuntary Separation from Service (as defined below)
from the Company. However, the Company’s Repurchase Option on such Restricted Shares shall lapse upon the occurrence of a Corporate
Transaction (as defined in this Section) if the Participant is in service on the date of the Corporate Transaction. Such Restricted Shares
shall be owned by the Participant without restriction when the Company’s Repurchase Option lapses. If the Participant voluntarily
separates from service before July 15, 2035 and the Company’s Repurchase Options have not lapsed by July 16, 2025 (with
respect to shares issued prior to that date) or July 15, 2035 (with respect to shares issued on or after July 16, 2025), the
Company will exercise its Repurchase Option as set forth below.”
2. The first sentence of
Section 4(e) of the LTIP is hereby replaced in its entirety so that such sentence reads as follows:
A “Triggering Event” means
the occurrence of either of the following before a Corporate Transaction: (i) voluntary Separation from Service by a Participant,
or (ii) the passage of 10 years from (A) the Effective Date (with respect to shares issued before July 16, 2025), or (B) July 15,
2025 (with respect to shares issued on or after July 16, 2025) without the Participant meeting the two conditions for lapse of the
Company’s Repurchase Option.”
3. The last sentence of Section 7
of the LTIP is hereby replaced in its entirety so that such section reads as follows:
“The LTIP shall continue
in effect until July 15, 2035, unless sooner terminated.”
4. Except as specifically
set forth herein, the terms of the LTIP shall be and remain unchanged, and the LTIP as amended shall remain in full force and effect.
The foregoing is hereby acknowledged
as being the Amendment to the Fortress Biotech, Inc. Amended and Restated Long Term Incentive Plan, as adopted by the Board on March 28,
2024, and approved by the Company’s stockholders on May 23, 2024.
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=FBIO_SeriesACumulativeRedeemablePerpetualPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Fortress Biotech (NASDAQ:FBIOP)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Fortress Biotech (NASDAQ:FBIOP)
Historical Stock Chart
Von Sep 2023 bis Sep 2024